HC Wainwright Has Positive Forecast for PHIO FY2026 Earnings

Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Free Report) – Investment analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Phio Pharmaceuticals in a note issued to investors on Monday, November 16th. HC Wainwright analyst M. Keller now expects that the company will earn ($1.41) per share for the year, up from their prior estimate of ($1.47). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2026 earnings at ($0.35) EPS and FY2027 earnings at ($0.73) EPS.

Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, hitting the consensus estimate of ($0.36).

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $14.00.

Read Our Latest Research Report on Phio Pharmaceuticals

Phio Pharmaceuticals Trading Down 0.7%

Shares of PHIO stock opened at $0.71 on Wednesday. Phio Pharmaceuticals has a 12 month low of $0.70 and a 12 month high of $1.88. The business’s 50 day moving average is $0.92 and its two-hundred day moving average is $1.07.

About Phio Pharmaceuticals

(Get Free Report)

Phio Pharmaceuticals is a clinical-stage biotechnology company developing treatments based on its INTASYL platform, a technology for delivering RNA interference compounds into cells to reduce the activity of selected genes. The company focuses on potential therapies for cancer, particularly approaches intended to strengthen the body’s immune response to tumors. Its pipeline includes candidates designed to target genes involved in immune regulation and tumor biology. These investigational treatments are being developed for solid tumors; they are not approved for commercial use.

Recommended Stories

Earnings History and Estimates for Phio Pharmaceuticals (NASDAQ:PHIO)

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.